Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy

Author(s): L.A. Pardo, D. Gomez-Varela, F. Major, K. Sansuk, R. Leurs, B.R. Downie, L.F. Tietze, W. Stuhmer.

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 5 , 2012

Become EABM
Become Reviewer

Abstract:

Kv10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, Kv10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, KV10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking Kv10.1 to cancer, and propose techniques that could exploit Kv10.1s properties for the management of cancer

Keywords: ADEPT, astemizole, cancer diagnosis, cancer prognosis, eag1, ether a go-go, imipramine, immunotherapy, immunotargeted therapy, KCNH1, KV10.1, potassium channel, tumor therapy

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 5
Year: 2012
Page: [675 - 682]
Pages: 8
DOI: 10.2174/092986712798992011
Price: $58

Article Metrics

PDF: 9